Company Filing History:
Years Active: 2004
Title: Carlo Heirman: Innovator in Cancer Research
Introduction
Carlo Heirman is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly through his work on tumor-associated genes. His innovative approach has led to advancements in the diagnosis and treatment of cancer.
Latest Patents
Heirman holds 1 patent for his invention titled "Mage-A3 peptides presented by HLA class molecules." This patent describes HLA class II binding peptides encoded by the MAGE-A3 tumor-associated gene. The invention also includes nucleic acids encoding such peptides and antibodies related to them. The peptides are designed to stimulate the activity and proliferation of CD4 T lymphocytes, which are crucial for the immune response against tumors. Additionally, the patent outlines methods and products for diagnosing and treating conditions characterized by the expression of the MAGE-A3 gene.
Career Highlights
Carlo Heirman is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer immunology. His work has been instrumental in understanding how the immune system can be harnessed to fight cancer more effectively.
Collaborations
Heirman has collaborated with notable colleagues such as Erwin Schultz and Pascal Chaux. These partnerships have further enriched his research and contributed to the development of innovative cancer therapies.
Conclusion
Carlo Heirman is a distinguished inventor whose work in cancer research has the potential to transform treatment approaches. His contributions, particularly in the area of MAGE-A3 peptides, highlight the importance of innovation in the fight against cancer.